From the markers evaluated in a study with 83 participants (44 MDS, 20 healthy subjects and 19 patients with non-MDS conditions), CD61, CD36 and CD42a were found decreased and CD34 was asynchronously expressed within the MDS group (110). This evidence concerns the gene CD34 and myelodysplastic syndrome.